{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-24-000007","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.256687+00:00","generated_at":"2026-06-05T05:38:18.709205+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amneal reports Q4 2023 net revenue $617M, GAAP loss $0.40 EPS; 2024 guidance $2.55-2.65B revenue","bullets":["Q4 net revenue $617M (+1% YoY); GAAP net loss $99M ($0.40 loss per share); adjusted EBITDA $142M (-8% YoY).","Full year 2023 net revenue $2.39B (+8%); GAAP net loss $84M; adjusted EBITDA $558M (+$44M YoY).","2024 guidance: net revenue $2.55-$2.65B; adjusted EBITDA $580-$620M.","Generics Q4 revenue -9% YoY on order timing; AvKARE +38% on launches; Specialty +2%."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-24-000007","json":"https://secwatch.observer/filing/0001723128-24-000007.json","markdown":"https://secwatch.observer/filing/0001723128-24-000007.md","text":"https://secwatch.observer/filing/0001723128-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000007/0001723128-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000007/amrx-20240301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:38:18.709205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"737f19ebcf086a742b1a1c527e75ae574caa5123","claim":"Amneal Pharmaceuticals, Inc. reported full year ended December 31, 2023 results: revenue $2.39 billion, net income GAAP Net Loss of $84 million, EPS Diluted Loss per Share of $0.48. Guidance initiated.","evidence_excerpt":"per Share of $0.40 ‒ ‒ Q4 2023 Adjusted Net Income (1) of $44 million, Adjusted EBITDA (1) of $142 million; Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Full Year 2023 Net Revenue of $2.39 billion; GAAP Net Loss of $84 million; Diluted Loss per Share of $0.48 ‒ ‒ Full Year 2023 Adjusted Net Income (1) of $198 million; Adjusted EBITDA (1) of $558 million; Adjusted Diluted","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000007/0001723128-24-000007-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2023"},{"label":"Revenue","value":"$2.39 billion"},{"label":"Net income","value":"GAAP Net Loss of $84 million"},{"label":"EPS","value":"Diluted Loss per Share of $0.48"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a54f773e1ff59c66577859cc077160740e71e216","claim":"Amneal Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $617 million, net income GAAP Net Loss of $99 million, EPS Diluted Loss per Share of $0.40. Guidance initiated.","evidence_excerpt":"--- AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ‒ Full Year 2023 Performance Met or Exceeded Financial Guidance Metrics – ‒ Q4 2023 Net Revenue of $617 million; GAAP Net Loss of $99 million; Diluted Loss per Share of $0.40 ‒ ‒ Q4 2023 Adjusted Net Income (1) of $44 million, Adjusted EBITDA (1) of $142 million; Adjusted Diluted EPS (1)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000007/0001723128-24-000007-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$617 million"},{"label":"Net income","value":"GAAP Net Loss of $99 million"},{"label":"EPS","value":"Diluted Loss per Share of $0.40"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}